l.Wednesday November 8, 2006
Sepsis Guidelines and bundle - Pro and Con

Con: In October 19, 2006 edition of The New England Journal of Medicine, an article published arguing that the whole sepsis guidelines are nothing but part of a commercial market strategy from company Eli Lilly to promote their drug "Xigris". In other words, it criticizes the whole surviving sepsis campaign and its major funding source, Eli Lilly as a business gimmick. This is a very strong provocative article and first time arguments have been brought against the whole idea of sepsis guidelines and bundle in a major journal and authors are none less but from Dept. of Critical Care, National institute of Health 1.

Pro: Dr. Mitchell M. Levy, M.D., Professor of Medicine at Brown Medical School and Medical Director of the Medical Intensive Care Unit at Rhode Island, and one of the vanguard of survivng sepsis guidelines answered these criticism while interviewing with Dr. Richard H. Savel, M.D., associte editor of SCCM podcast.

Being an intensivist, this is an important debate to be aware of. We are attaching here the link of the interview at SCCM podcast with courtesy and permission of Dr. Savel, Associate Director, Surgical Intensive Care Unit, Maimonides Medical Center and Assistant Professor of Medicine, Mt. Sinai School of Medicine, NY.
(Thanks Dr. Savel).


To listen to the interview click here. (SCCM pod # 49)
To download the interview click here.

(Total time 35 minutes)


Related sites:

iCritical Care (SCCM)

Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock




Reference:

1. Surviving Sepsis — Practice Guidelines, Marketing Campaigns, and Eli Lilly - Volume 355:1640-1642, Number 16, October 19, 2006 - The New England Journal of Medicine.